Developing Translational Vaccines Against Heroin and Fentanyl Through Investigation of Adjuvants and Stability

Overview

Journal Mol Pharm

Publisher American Chemical Society

Specialty Pharmacology

Date 2020 Dec 10

PMID 33301675

Citations 11

Authors

Steven Blake

Paul T Bremer

Bin Zhou

Nikolai Petrovsky

Lauren C Smith

Candy S Hwang

Kim D Janda

Affiliations

Soon will be listed here.

Abstract

The nearly insurmountable adversity that accompanies opioid use disorder (OUD) creates life-altering complications for opioid users. To worsen matters, existing small-molecule drugs continue to inadequately address OUD due to their engagement of the opioid receptor, which can leave the user to deal with side effects and financial hardships from their repeated use. An alternative therapeutic approach utilizes endogenously generated antibodies through active vaccination to reduce the effect of opioids without modulating the opioid receptor. Here, we explore different adjuvants and storage conditions to improve opioid vaccine efficacy and shelf life. Our results revealed that inulin-based formulations (Advax) containing a CpG oligodeoxynucleotide (ODN) acted as effective adjuvants when combined with a heroin conjugate: immunized mice showed excellent recovery from heroin-induced antinociception accompanied by high titer, high opioid affinity serum antibodies similar to the immunopotentiating properties of traditional alum-based adjuvants. Moreover, nonhuman primates vaccinated with a heroin/fentanyl combination vaccine demonstrated potent antibody responses against opioids when formulated with both inulin and alum adjuvants. Finally, storing a freeze-dried opioid vaccine formulation maintained efficacy for up 1 year at room temperature. The results from our studies represent an advance toward a clinically feasible opioid vaccine.

Citing Articles

The development of opioid vaccines as a novel strategy for the treatment of opioid use disorder and overdose prevention.

Tuncturk M, Kushwaha S, Heider BS R, Heider R, Oesterle T, Weinshilboum R Int J Neuropsychopharmacol. 2025; 28(2).

PMID: 39831679 PMC: 11792077. DOI: 10.1093/ijnp/pyaf005.

Conjugation of Multiple Proteins Onto the Surface of PLGA/Lipid Hybrid Nanoparticles.

Hu H, Zhang C J Biomed Mater Res A. 2024; 113(1):e37807.

PMID: 39420678 PMC: 11669531. DOI: 10.1002/jbm.a.37807.

Opioid-Based Haptens: Development of Immunotherapy.

Hosztafi S, Galambos A, Koteles I, Karadi D, Furst S, Al-Khrasani M Int J Mol Sci. 2024; 25(14).

PMID: 39063024 PMC: 11277321. DOI: 10.3390/ijms25147781.

Enhancing Protective Antibodies against Opioids through Antigen Display on Virus-like Particles.

Shafieichaharberoud F, Lang S, Whalen C, Rivera Quiles C, Purcell L, Talbot C Bioconjug Chem. 2023; 35(2):164-173.

PMID: 38113481 PMC: 11259974. DOI: 10.1021/acs.bioconjchem.3c00415.

Advax-CpG55.2-adjuvanted monovalent or trivalent SARS-CoV-2 recombinant spike protein vaccine protects hamsters against heterologous infection with Beta or Delta variants.

Honda-Okubo Y, Bowen R, Barker M, Bielefeldt-Ohmann H, Petrovsky N Vaccine. 2023; 41(48):7116-7128.

PMID: 37863669 PMC: 10873063. DOI: 10.1016/j.vaccine.2023.10.018.

References

Stronsky S, Cooper C, Steffens J, Van Tongeren S, Bavari S, Martins K . Adjuvant selection impacts the correlates of vaccine protection against Ebola infection. Vaccine. 2020; 38(29):4601-4608. PMC: 7272269. DOI: 10.1016/j.vaccine.2020.05.009. View

Kanof P, Handelsman L, ARONSON M, Ness R, Cochrane K, Rubinstein K . Clinical characteristics of naloxone-precipitated withdrawal in human opioid-dependent subjects. J Pharmacol Exp Ther. 1992; 260(1):355-63. View

Cooper P, Petrovsky N . Delta inulin: a novel, immunologically active, stable packing structure comprising β-D-[2 -> 1] poly(fructo-furanosyl) α-D-glucose polymers. Glycobiology. 2010; 21(5):595-606. PMC: 3106373. DOI: 10.1093/glycob/cwq201. View

Lees A, FINKELMAN F, INMAN J, Witherspoon K, Johnson P, Kennedy J . Enhanced immunogenicity of protein-dextran conjugates: I. Rapid stimulation of enhanced antibody responses to poorly immunogenic molecules. Vaccine. 1994; 12(13):1160-6. DOI: 10.1016/0264-410x(94)90237-2. View

Bremer P, Schlosburg J, Banks M, Steele F, Zhou B, Poklis J . Development of a Clinically Viable Heroin Vaccine. J Am Chem Soc. 2017; 139(25):8601-8611. PMC: 5612493. DOI: 10.1021/jacs.7b03334. View

Skwarczynski M . Inulin: A New Adjuvant With Unknown Mode of Action. EBioMedicine. 2016; 15:8-9. PMC: 5233799. DOI: 10.1016/j.ebiom.2016.11.019. View

Ignar D, Kuhn C . Effects of specific mu and kappa opiate tolerance and abstinence on hypothalamo-pituitary-adrenal axis secretion in the rat. J Pharmacol Exp Ther. 1990; 255(3):1287-95. View

Raleigh M, Laudenbach M, Baruffaldi F, Peterson S, Roslawski M, Birnbaum A . Opioid Dose- and Route-Dependent Efficacy of Oxycodone and Heroin Vaccines in Rats. J Pharmacol Exp Ther. 2018; 365(2):346-353. PMC: 5884377. DOI: 10.1124/jpet.117.247049. View

Peek L, Martin T, Elk Nation C, Pegram S, Middaugh C . Effects of stabilizers on the destabilization of proteins upon adsorption to aluminum salt adjuvants. J Pharm Sci. 2006; 96(3):547-57. DOI: 10.1002/jps.20762. View

10.

Counoupas C, Pinto R, Nagalingam G, Britton W, Petrovsky N, Triccas J . Delta inulin-based adjuvants promote the generation of polyfunctional CD4 T cell responses and protection against Mycobacterium tuberculosis infection. Sci Rep. 2017; 7(1):8582. PMC: 5561132. DOI: 10.1038/s41598-017-09119-y. View

11.

Matyas G, Mayorov A, Rice K, Jacobson A, Cheng K, Iyer M . Liposomes containing monophosphoryl lipid A: a potent adjuvant system for inducing antibodies to heroin hapten analogs. Vaccine. 2013; 31(26):2804-10. PMC: 4120113. DOI: 10.1016/j.vaccine.2013.04.027. View

12.

Nestler E . From neurobiology to treatment: progress against addiction. Nat Neurosci. 2002; 5 Suppl:1076-9. DOI: 10.1038/nn945. View

13.

Anton B, Salazar A, Flores A, Matus M, Marin R, Hernandez J . Vaccines against morphine/heroin and its use as effective medication for preventing relapse to opiate addictive behaviors. Hum Vaccin. 2009; 5(4):214-29. DOI: 10.4161/hv.5.4.7556. View

14.

Sanderson S, Cheruku S, Padmanilayam M, Vennerstrom J, Thiele G, Palmatier M . Immunization to nicotine with a peptide-based vaccine composed of a conformationally biased agonist of C5a as a molecular adjuvant. Int Immunopharmacol. 2003; 3(1):137-46. DOI: 10.1016/s1567-5769(02)00260-6. View

15.

Wang X, Li B, Zhou X, Liao Y, Tang J, Liu T . Changes in brain gray matter in abstinent heroin addicts. Drug Alcohol Depend. 2012; 126(3):304-8. DOI: 10.1016/j.drugalcdep.2012.05.030. View

16.

Bremer P, Janda K . Conjugate Vaccine Immunotherapy for Substance Use Disorder. Pharmacol Rev. 2017; 69(3):298-315. PMC: 5482184. DOI: 10.1124/pr.117.013904. View

17.

Selley D, Cao C, Sexton T, Schwegel J, Martin T, Childers S . mu Opioid receptor-mediated G-protein activation by heroin metabolites: evidence for greater efficacy of 6-monoacetylmorphine compared with morphine. Biochem Pharmacol. 2001; 62(4):447-55. DOI: 10.1016/s0006-2952(01)00689-x. View

18.

Tenney R, Blake S, Bremer P, Zhou B, Hwang C, Poklis J . Vaccine blunts fentanyl potency in male rhesus monkeys. Neuropharmacology. 2019; 158:107730. PMC: 6745253. DOI: 10.1016/j.neuropharm.2019.107730. View

19.

Hwang C, Bremer P, Wenthur C, Ho S, Chiang S, Ellis B . Enhancing Efficacy and Stability of an Antiheroin Vaccine: Examination of Antinociception, Opioid Binding Profile, and Lethality. Mol Pharm. 2018; 15(3):1062-1072. PMC: 5912936. DOI: 10.1021/acs.molpharmaceut.7b00933. View

20.

Lugoboni F, Zamboni L, Cibin M, Tamburin S . Intravenous Misuse of Methadone, Buprenorphine and Buprenorphine-Naloxone in Patients Under Opioid Maintenance Treatment: A Cross-Sectional Multicentre Study. Eur Addict Res. 2019; 25(1):10-19. DOI: 10.1159/000496112. View